News
Peli BioThermal Opens India Service Centre
New service centre expands company global footprint in region of key growth in pharma manufacturingand distribution
Peli BioThermal, the global name in temperature controlled packaging solutions, announces the opening of its latest service centre located in India.The new service centre...
Drug Research
Operations commence at Genezen’s lenti- and retroviral vector process development lab
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has officially opened its new process development and analytical lab.
The lab will deliver a full...
News
Concept Life Sciences celebrates GMP accreditation
Concept Life Sciences (CLS), a Malvern Panalytical brand, has announced that it has received certification of compliance with Good Manufacturing Practice (GMP) for the production of active substances at its site in Sandwich, UK. This is the successful outcome of...
Drug Research
Nykode Therapeutics Selects BioConnection to Manufacture Lead Vax Candidate
Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new...
Drug Research
Lonza and Bioqube Ventures Sign a Framework Agreement for the Future Development of Biologics and Small Molecules for Bioqubes Portfolio Companies
Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced a framework agreement covering a strategic collaboration...
Drug Research
Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001
Valneva SE, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years....
Clinical Trials
Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19
Emmes announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















